Interferon beta-1b biosimilar (Amega Biotech/Actover Pharmaceutical)

干扰素β-1b生物类似药 (Amega Biotech/Actover Pharmaceutical)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon beta-1b biosimilar (Amega Biotech/Actover Pharmaceutical)
Drug Alias Name干扰素β-1b生物仿制药 (Amega Biotech/Actover Pharmaceutical)Actoferon
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIran
Original Approved Date2014/01/01
Country/TerritoryIran
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmega Biotech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeL03AB08
Related LinksN/A